Navigation Links
Link between Obesity and Post-Radiotherapy Outcome in Prostate Cancer Patients

A new study with obese men having prostrate cancer finds a close link between the failure of radiation therapy and increased body mass index (BMI). //

Obese people are at a higher risk for developing failures in clinical, biochemical and radiation therapy – a new study published in a peer-reviewed journal of the American Cancer Society says.

Evidence has increasingly shown that obesity has a deleterious effect on the human body, from the risk of diabetes to joint disease. Obesity has more recently been shown to play a significant role in the development of some cancers, including cancers of the breast, prostate, colon, and many others. Obesity has also been associated with the progression of disease. Obese men with prostate cancer often have more aggressive disease and higher mortality rates. Researchers postulate that fat tissue influences concentrations of various significant signaling molecules, such as testosterone, estrogen, insulin and insulin-like growth factor, which play a role in prostate cancer development and progression.

There is already a body of scientific evidence demonstrating that obesity is linked to treatment failure after prostatectomy. However, there are no data on the effects of obesity on the effectiveness of radiation treatment for prostate cancer. Sara Strom, Ph.D. of the University of Texas M. D. Anderson Cancer Center in Houston and colleagues reviewed the medical records of 873 patients who received radiotherapy alone for prostate cancer. Among the group, 18 percent were mildly obese and 5 percent were moderately to severely obese.

After an average 96 months of follow-up, 295 of the men had three consecutive increases in blood PSA, indicating biochemical failure. Meanwhile, 127 of the men had clinical failure (local recurrence and/or distant metastasis) determined by radiologic studies, biopsy, or physical examination. On analysis, risk of biochemical and clinical failure were influenced by BMI. As BMI increased, the risk of disease progression following therapy also increased. For example, men who were moderately or severely obese were at double the risk for biochemical failure than other men who were not.

The authors conclude, 'our findings validate the importance of obesity in prostate cancer progression and suggest a link to the biology of this tumor.'

To understand the influence of obesity on treatment and possibly exploit that understanding to improve treatment outcome, 'future studies should evaluate the relationship of obesity with dietary factors, genetic modifiers of steroid androgen metabolism, insulin, and a detailed investigation of the insulin growth factor pathway to explore the underlying mechanisms of action in prostate carcinogenesis,' suggest the authors.

(Source: Eurekalert)
'"/>




Related medicine news :

1. CDC reveals relationship between prepregnant weight and heart defects in infants
2. Link between Constipation and Parkinsons Disease
3. Is there a link between bones and memory?
4. Comparison between warfarin and aspirin
5. No link between blood groups and prostate cancer
6. Link between chlorine byproducts and pregnancy risks
7. No link between bad weather and rheumatism
8. No connection between breast cancer and pill
9. No connection between epidurals and backache
10. Link between birth weight and Insulin Resistance
11. Link between athleticism and neurological disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles and ... on resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a northern ... the greater DC region, is inaugurating a “New Leash On Life” charity initiative ... training them to be companions for veterans in need. , The Semper K9 ...
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: